TWI324604B
(en)
*
|
2003-06-18 |
2010-05-11 |
Novartis Ag |
New use of staurosporine derivatives
|
WO2005011598A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
US20070191338A1
(en)
*
|
2003-08-08 |
2007-08-16 |
Atadja Peter W |
Combinations comprising staurosporines
|
WO2005027910A1
(en)
|
2003-08-25 |
2005-03-31 |
Dana-Farber Cancer Institute Inc. |
Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
|
EP1684762A4
(de)
|
2003-11-13 |
2009-06-17 |
Ambit Biosciences Corp |
Harnstoff-derivate als kinase-modulatoren
|
WO2005053704A1
(en)
*
|
2003-12-01 |
2005-06-16 |
Novartis Ag |
Method for predicting drug responsiveness in myeloid neoplasms
|
EP1699477A2
(de)
*
|
2003-12-11 |
2006-09-13 |
Theravance, Inc. |
Zusammensetzungen zur verwendung bei der behandlung von durch mutierte rezeptor-tyrosinkinase angetriebene zellproliferationserkrankungen
|
JP5704785B2
(ja)
*
|
2004-07-19 |
2015-04-22 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
免疫抑制のためのflt3阻害剤
|
GB0419159D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
CN101106983A
(zh)
*
|
2004-11-24 |
2008-01-16 |
诺瓦提斯公司 |
JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
|
GB0426821D0
(en)
*
|
2004-12-07 |
2005-01-12 |
Novartis Ag |
Organic compounds
|
CA2606783C
(en)
|
2005-05-10 |
2014-03-25 |
Incyte Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
MX2008000900A
(es)
*
|
2005-07-20 |
2008-03-18 |
Novartis Ag |
Combinacion que comprende pirimidil-amino-benzamidas y un inhibidor de flt-3 para el tratamiento de enfermedades proliferativas.
|
WO2007038215A1
(en)
|
2005-09-22 |
2007-04-05 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
US7795279B2
(en)
|
2005-10-18 |
2010-09-14 |
Janssen Pharmaceutica Nv |
Method of inhibiting FLT3 kinase
|
GB0522932D0
(en)
*
|
2005-11-10 |
2005-12-21 |
Univ Southampton |
PKC412 in treatment of atypical chronic myeloid leukemia
|
JP5308820B2
(ja)
*
|
2005-11-14 |
2013-10-09 |
ウニヴェルジテート・チューリッヒ |
胞巣状横紋筋肉腫に使用するためのスタウロスポリン誘導体
|
EP2348023B9
(de)
|
2005-12-13 |
2017-03-08 |
Incyte Holdings Corporation |
Heteroarylsubstituierte pyrrolo[2,3-b]pyridine und pyrrolo[2,3-b]pyrimidine als januskinaseinhibitoren
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
EP2021335B1
(de)
|
2006-04-20 |
2011-05-25 |
Janssen Pharmaceutica N.V. |
Heterocyclische verbindungen als c-fms-kinasehemmer
|
MX2008013530A
(es)
|
2006-04-20 |
2009-01-14 |
Janssen Pharmaceutica Nv |
Inhibidores de c-fms cinasa.
|
GB0612542D0
(en)
*
|
2006-06-23 |
2006-08-02 |
Novartis Ag |
Combinations comprising staurosporines
|
JP5492565B2
(ja)
|
2006-12-22 |
2014-05-14 |
インサイト・コーポレイション |
Janusキナーゼ阻害剤としての置換複素環
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
CN101932582B
(zh)
|
2007-06-13 |
2013-09-25 |
因塞特公司 |
詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
EP2220068B1
(de)
|
2007-11-16 |
2016-01-27 |
Incyte Holdings Corporation |
4-pyrazolyl-n-arylpyrimidin-2-amine und 4-pyrazolyl-n-heteroarylpyrimidin-2-amine als janus-kinase-inhibitoren
|
UA101493C2
(ru)
|
2008-03-11 |
2013-04-10 |
Инсайт Корпорейшн |
Производные азетидина и циклобутана как ингибиторы jak
|
JP2011518836A
(ja)
|
2008-04-24 |
2011-06-30 |
インサイト・コーポレイション |
大環状化合物およびそれらのキナーゼ阻害剤としての使用
|
PT2824100T
(pt)
|
2008-07-08 |
2018-05-10 |
Incyte Holdings Corp |
1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
CN102458581B
(zh)
|
2009-05-22 |
2016-03-30 |
因塞特控股公司 |
作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2,3-d]嘧啶和吡咯-3-基-吡咯并[2,3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
ME01838B
(me)
|
2009-06-29 |
2014-12-20 |
Lncyte Holdings Corp |
Pirimidinoni kao inhibitori pi3k
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
KR20180126619A
(ko)
|
2009-10-09 |
2018-11-27 |
인사이트 홀딩스 코포레이션 |
3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
|
EP2327706A1
(de)
*
|
2009-11-30 |
2011-06-01 |
Novartis AG |
Polymorphe Formen III und IV von N-Benzoyl-Staurosporin
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
US8680108B2
(en)
|
2009-12-18 |
2014-03-25 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
HUE045270T2
(hu)
|
2010-01-05 |
2019-12-30 |
Inst Nat Sante Rech Med |
FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
|
CN102812022B
(zh)
|
2010-01-12 |
2016-02-03 |
Ab科学有限公司 |
噻唑和噁唑激酶抑制剂
|
BR112012020693B1
(pt)
|
2010-02-18 |
2020-05-12 |
Incyte Holdings Corporation |
Derivados de ciclobutano e metilciclobutano como inibidores de janus quinase e composição que os compreende
|
ME02386B
(de)
|
2010-03-10 |
2016-09-20 |
Incyte Holdings Corp |
Piperidin-4-yl azetidinderivate als jak1-inhibitoren
|
US9193721B2
(en)
|
2010-04-14 |
2015-11-24 |
Incyte Holdings Corporation |
Fused derivatives as PI3Kδ inhibitors
|
KR102303885B1
(ko)
|
2010-05-21 |
2021-09-24 |
인사이트 홀딩스 코포레이션 |
Jak 저해제에 대한 국소 제형
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
EP2640723A1
(de)
|
2010-11-19 |
2013-09-25 |
Incyte Corporation |
Cyclobutyl-substituierte pyrrolopyridin- und pyrrolopyrimidinderivate als jak-inhibitoren
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
EP2655374B1
(de)
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(substituierte phenyl)ethyl)-9h-purin-6-amine als pi3k-hemmer
|
CA2827673C
(en)
|
2011-02-18 |
2020-10-27 |
Novartis Pharma Ag |
Mtor/jak inhibitor combination therapy
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
CA2844507A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
Jak pi3k/mtor combination therapy
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
MX2020004502A
(es)
|
2011-09-02 |
2022-01-20 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k).
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
KR20150004834A
(ko)
*
|
2012-04-24 |
2015-01-13 |
인터내셔날 스템 셀 코포레이션 |
사람 만능 줄기 세포부터의 신경 줄기 세포 및 도파민성 뉴런의 유도
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
UA117347C2
(uk)
|
2012-06-13 |
2018-07-25 |
Інсайт Холдинґс Корпорейшн |
Заміщені трициклічні сполуки як інгібітори fgfr
|
US9303046B2
(en)
|
2012-08-07 |
2016-04-05 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
TWI569799B
(zh)
|
2012-09-21 |
2017-02-11 |
安羅格製藥股份有限公司 |
抑制組成型活性磷酸化flt3激酶的方法
|
PE20151141A1
(es)
|
2012-11-01 |
2015-08-06 |
Incyte Corp |
Derivados triciclicos fusionados de tiofeno como inhibidores de jak
|
EA201590930A1
(ru)
|
2012-11-15 |
2015-08-31 |
Инсайт Корпорейшн |
Лекарственные формы руксолитиниба с замедленным высвобождением
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
TW202214254A
(zh)
|
2013-03-01 |
2022-04-16 |
美商英塞特控股公司 |
吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
|
JP6397831B2
(ja)
|
2013-03-06 |
2018-09-26 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤の製造方法及びその中間体
|
CN105263931B
(zh)
|
2013-04-19 |
2019-01-25 |
因赛特公司 |
作为fgfr抑制剂的双环杂环
|
ME02763B
(de)
|
2013-05-17 |
2018-01-20 |
Incyte Corp |
Bipyrazolderivate als jak-inhibitoren
|
MY195091A
(en)
|
2013-08-07 |
2023-01-10 |
Incyte Corp |
Sustained Release Dosage Forms for a JAK1 Inhibitor
|
JP2016528288A
(ja)
|
2013-08-20 |
2016-09-15 |
インサイト・コーポレイションIncyte Corporation |
上昇したc反応性タンパク質レベルを有する固形腫瘍の患者における延命効果
|
US10463658B2
(en)
*
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
SI3110409T1
(sl)
|
2014-02-28 |
2018-11-30 |
Incyte Corporation |
Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov
|
KR20220126813A
(ko)
|
2014-03-14 |
2022-09-16 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
KR20230044320A
(ko)
|
2014-04-08 |
2023-04-03 |
인사이트 코포레이션 |
Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료
|
SG10201809518QA
(en)
|
2014-04-30 |
2018-11-29 |
Incyte Corp |
Processes of preparing a jak1 inhibitor and new forms thereto
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
CN107001283B
(zh)
|
2014-07-31 |
2021-05-25 |
国家健康与医学研究院 |
Flt3受体拮抗剂
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
US9586949B2
(en)
|
2015-02-09 |
2017-03-07 |
Incyte Corporation |
Aza-heteroaryl compounds as PI3K-gamma inhibitors
|
UA121669C2
(uk)
|
2015-02-20 |
2020-07-10 |
Інсайт Корпорейшн |
Біциклічні гетероцикли як інгібітори fgfr
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
CR20170389A
(es)
|
2015-02-27 |
2018-01-26 |
Incyte Corp |
Sales de inhibidor de p13k y procesos de preparación
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック,インク. |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
WO2016183062A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
EP3878465A1
(de)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Kombinationstherapien mit antikörpermolekülen gegen tim-3
|
RS63125B1
(sr)
|
2015-11-03 |
2022-05-31 |
Janssen Biotech Inc |
Antitela koja se specifično vezuju za pd-1 i njihova upotreba
|
MD3371190T2
(ro)
|
2015-11-06 |
2022-09-30 |
Incyte Corp |
Compuși heterociclici ca inhibitori PI3K-gamma
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
EP3400221B1
(de)
|
2016-01-05 |
2020-08-26 |
Incyte Corporation |
Pyrazol und imidazol substituierte pyridine als pi3k-gamma-hemmstoffe
|
CN106083830B
(zh)
*
|
2016-06-01 |
2019-07-12 |
中国海洋大学 |
双吲哚马来酰亚胺衍生物及其制备方法和用途
|
EP3254698A1
(de)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3-rezeptor-inhibitoren bei niedriger dosierung zur behandlung von neuropathischem schmerz
|
AR108875A1
(es)
|
2016-06-24 |
2018-10-03 |
Incyte Corp |
COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
KR20180074792A
(ko)
|
2016-11-02 |
2018-07-03 |
아로그 파마슈티칼스, 인코퍼레이티드 |
돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
EP3624780A1
(de)
|
2017-05-17 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3-inhibitoren zur verbesserung von schmerzbehandlungen durch opioide
|
WO2018217766A1
(en)
|
2017-05-22 |
2018-11-29 |
Whitehead Institute For Biomedical Research |
Kcc2 expression enhancing compounds and uses thereof
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
CN107417743B
(zh)
*
|
2017-06-15 |
2020-07-21 |
杭州科兴生物化工有限公司 |
星孢菌素醛基取代衍生物及其制备方法和应用
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
PE20210169A1
(es)
|
2017-10-18 |
2021-01-29 |
Incyte Corp |
Derivados de imidazol condensados sustituidos por grupos de hidroxia terciaria como inhibidores de pi3k-y gamma
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019126505A1
(en)
|
2017-12-21 |
2019-06-27 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
|
CR20200379A
(es)
|
2018-01-30 |
2021-03-05 |
Incyte Corp |
Procesos e intermedio para elaborar un inhibidor de jak campo técnico
|
KR20200128043A
(ko)
|
2018-02-16 |
2020-11-11 |
인사이트 코포레이션 |
사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
|
JP7474709B2
(ja)
|
2018-02-27 |
2024-04-25 |
インサイト・コーポレイション |
A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
|
PT3762368T
(pt)
|
2018-03-08 |
2022-05-06 |
Incyte Corp |
Compostos de aminopirazina diol como inibidores de pi3k-y
|
MA52655A
(fr)
|
2018-03-30 |
2021-02-17 |
Incyte Corp |
Biomarqueurs pour maladie cutanée inflammatoire
|
CA3095487A1
(en)
|
2018-03-30 |
2019-10-03 |
Incyte Corporation |
Treatment of hidradenitis suppurativa using jak inhibitors
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
SG11202010636VA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
US11168089B2
(en)
|
2018-05-18 |
2021-11-09 |
Incyte Corporation |
Fused pyrimidine derivatives as A2A / A2B inhibitors
|
MA52754A
(fr)
|
2018-05-25 |
2021-04-14 |
Incyte Corp |
Composés hétérocycliques tricycliques en tant qu'activateurs de sting
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2020010003A1
(en)
|
2018-07-02 |
2020-01-09 |
Incyte Corporation |
AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
|
GEP20237560B
(en)
|
2018-07-05 |
2023-10-25 |
Incyte Corp |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
WO2020028566A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
WO2020028565A1
(en)
|
2018-07-31 |
2020-02-06 |
Incyte Corporation |
Tricyclic heteraryl compounds as sting activators
|
DK3847175T3
(da)
|
2018-09-05 |
2024-03-18 |
Incyte Corp |
Krystallinske former af en phosphoinositid-3-kinase- (pi3k) inhibitor
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
JP2022508055A
(ja)
|
2018-11-01 |
2022-01-19 |
サイロス ファーマシューティカルズ, インコーポレイテッド |
サイクリン依存性キナーゼ7(cdk7)の阻害剤
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
US11396502B2
(en)
|
2018-11-13 |
2022-07-26 |
Incyte Corporation |
Substituted heterocyclic derivatives as PI3K inhibitors
|
US11078204B2
(en)
|
2018-11-13 |
2021-08-03 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
US20220040324A1
(en)
|
2018-12-21 |
2022-02-10 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
WO2020146237A1
(en)
|
2019-01-07 |
2020-07-16 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
MA54947A
(fr)
|
2019-02-15 |
2021-12-22 |
Incyte Corp |
Biomarqueurs de kinase 2 dépendant de la cycline et leurs utilisations
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
US11919904B2
(en)
|
2019-03-29 |
2024-03-05 |
Incyte Corporation |
Sulfonylamide compounds as CDK2 inhibitors
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
CA3150975A1
(en)
|
2019-06-10 |
2020-12-17 |
Incyte Corporation |
Topical treatment of vitiligo by a jak inhibitor
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
WO2021022172A1
(en)
|
2019-08-01 |
2021-02-04 |
Incyte Corporation |
A dosing regimen for an ido inhibitor
|
JP2023509260A
(ja)
|
2019-08-14 |
2023-03-08 |
インサイト・コーポレイション |
Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物
|
KR20220066074A
(ko)
|
2019-08-26 |
2022-05-23 |
인사이트 코포레이션 |
A2a / a2b 억제제로서의 트리아졸로피리미딘
|
US11839619B2
(en)
|
2019-09-16 |
2023-12-12 |
The Regents Of The University Of California |
Methods for treatment of pediatric systemic mastocytosis
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
WO2021072232A1
(en)
|
2019-10-11 |
2021-04-15 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
PE20221085A1
(es)
|
2019-10-14 |
2022-07-05 |
Incyte Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
JP2023506118A
(ja)
|
2019-10-16 |
2023-02-15 |
インサイト・コーポレイション |
皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
CN115151539A
(zh)
|
2019-12-04 |
2022-10-04 |
因赛特公司 |
Fgfr抑制剂的衍生物
|
WO2021113479A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
IL296065A
(en)
|
2020-03-06 |
2022-10-01 |
Incyte Corp |
Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
|
JP2023522202A
(ja)
|
2020-04-16 |
2023-05-29 |
インサイト・コーポレイション |
融合三環式kras阻害剤
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
EP4157831A1
(de)
|
2020-06-02 |
2023-04-05 |
Incyte Corporation |
Verfahren zur herstellung eines jak1-inhibitors
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2022019998A1
(en)
|
2020-07-20 |
2022-01-27 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
EP4213800A1
(de)
|
2020-09-16 |
2023-07-26 |
Incyte Corporation |
Topische behandlung von vitiligo
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
CA3204374A1
(en)
|
2020-12-08 |
2022-06-16 |
Incyte Corporation |
Jak1 pathway inhibitors for the treatment of vitiligo
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
JP2024513575A
(ja)
|
2021-04-12 |
2024-03-26 |
インサイト・コーポレイション |
Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
EP4352060A1
(de)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclische heterocyclen als fgfr-inhibitoren
|
AU2022306671A1
(en)
|
2021-07-07 |
2024-01-25 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
WO2023287896A1
(en)
|
2021-07-14 |
2023-01-19 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
WO2023034290A1
(en)
|
2021-08-31 |
2023-03-09 |
Incyte Corporation |
Naphthyridine compounds as inhibitors of kras
|
US20230151005A1
(en)
|
2021-09-21 |
2023-05-18 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of kras
|
CA3234375A1
(en)
|
2021-10-01 |
2023-04-06 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
TW202320792A
(zh)
|
2021-11-22 |
2023-06-01 |
美商英塞特公司 |
包含fgfr抑制劑及kras抑制劑之組合療法
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
US20230183251A1
(en)
|
2021-12-10 |
2023-06-15 |
Incyte Corporation |
Bicyclic amines as cdk12 inhibitors
|
WO2023122134A1
(en)
|
2021-12-22 |
2023-06-29 |
Incyte Corporation |
Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
WO2023116884A1
(en)
|
2021-12-24 |
2023-06-29 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
US20230279004A1
(en)
|
2022-03-07 |
2023-09-07 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
WO2023245053A1
(en)
|
2022-06-14 |
2023-12-21 |
Incyte Corporation |
Solid forms of a jak inhibitor and process of preparing the same
|
CN114853784B
(zh)
*
|
2022-06-16 |
2023-09-05 |
贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) |
一种十字孢碱类化合物及其制备方法与应用
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
WO2024015731A1
(en)
|
2022-07-11 |
2024-01-18 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
WO2024030600A1
(en)
|
2022-08-05 |
2024-02-08 |
Incyte Corporation |
Treatment of urticaria using jak inhibitors
|